Oncogenic mutations in the TP53 and PI-3 kinase/AKT pathway are independent predictors of survival for advanced thyroid cancer: Analysis from the Molecular Screening and Therapeutics (MoST) program.

Autor: Novis E; St Vincent's Hospital, Sydney, NSW, Australia; St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia., Glover A; St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia. Electronic address: an.glover@garvan.org.au., Grady JP; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; Omico, the Australian Genomic Cancer Medicine Centre, Kensington, NSW, Australia; Centre for Molecular Oncology, University of New South Wales, Sydney, NSW, Australia., Silvestri A; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; Omico, the Australian Genomic Cancer Medicine Centre, Kensington, NSW, Australia; Centre for Molecular Oncology, University of New South Wales, Sydney, NSW, Australia., Thavaneswaran S; St Vincent's Hospital, Sydney, NSW, Australia; St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; The NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia., Lin F; The NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia., Ballinger ML; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; Omico, the Australian Genomic Cancer Medicine Centre, Kensington, NSW, Australia; Centre for Molecular Oncology, University of New South Wales, Sydney, NSW, Australia., Thomas DM; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; Omico, the Australian Genomic Cancer Medicine Centre, Kensington, NSW, Australia; Centre for Molecular Oncology, University of New South Wales, Sydney, NSW, Australia.

Publikováno v: Surgery [Surgery] 2025 Jan; Vol. 177, pp. 108858. Date of Electronic Publication: 2024 Oct 18.

Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma.

Autor: Gianferante DM; Division of Cancer Epidemiology and Genetics, NCI, NIH, Rockville, MD, USA., Moore A; Division of Cancer Epidemiology and Genetics, NCI, NIH, Rockville, MD, USA., Spector LG; Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA., Wheeler W; Information Management Services, Rockville, MD, USA., Yang T; Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA., Hubbard A; Division of Cancer Epidemiology and Genetics, NCI, NIH, Rockville, MD, USA., Gorlick R; University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patiño-Garcia A; Department of Pediatrics and Solid Tumor Division CIMA, IdiSNA, Clínica Universidad de Navarra, Pamplona, Spain., Lecanda F; Center for Applied Medical Research (CIMA)-University of Navarra, IdiSNA, and CIBERONC, Pamplona, Spain., Flanagan AM; UCL Cancer Institute, Huntley Street, London WC1E 6BT, UK; Royal National Orthopaedic Hospital NHS Trust, Stanmore, Middlesex HA7 4LP, UK., Amary F; Royal National Orthopaedic Hospital NHS Trust, Stanmore, Middlesex HA7 4LP, UK., Andrulis IL; Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada., Wunder JS; Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada., Thomas DM; Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia., Ballinger ML; Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia., Serra M; Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy; IRCCS Istituto Ortopedico Rizzoli, Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, Pharmacogenomics and Pharmacogenetics Research Unit, Bologna, Italy., Hattinger C; Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy; IRCCS Istituto Ortopedico Rizzoli, Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, Pharmacogenomics and Pharmacogenetics Research Unit, Bologna, Italy., Demerath E; Division of Epidemiology and Clinical Research, School of Public Health, UMN, USA., Johnson W; School of Sport, Exercise, and Health Sciences, University of Loughborough, UK., Birmann BM; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., De Vivo I; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA., Giles G; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia., Teras LR; Department of Population Science, American Cancer Society, Atlanta, GA, USA., Arslan A; Department of Obstetrics and Gynecology, New York School of Medicine, New York, NY, USA; Department of Population Health, New York University School of Medicine, New York, NY, USA., Vermeulen R; Institute for Risk Assessment Sciences, Utrecht University, Utrecht, the Netherlands; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands., Sample J; Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA., Freedman ND; Division of Cancer Epidemiology and Genetics, NCI, NIH, Rockville, MD, USA., Huang WY; Division of Cancer Epidemiology and Genetics, NCI, NIH, Rockville, MD, USA., Chanock SJ; Division of Cancer Epidemiology and Genetics, NCI, NIH, Rockville, MD, USA., Savage SA; Division of Cancer Epidemiology and Genetics, NCI, NIH, Rockville, MD, USA., Berndt SI; Division of Cancer Epidemiology and Genetics, NCI, NIH, Rockville, MD, USA., Mirabello L; Division of Cancer Epidemiology and Genetics, NCI, NIH, Rockville, MD, USA. Electronic address: mirabellol@nih.gov.

Publikováno v: Cancer epidemiology [Cancer Epidemiol] 2024 Oct; Vol. 92, pp. 102432. Date of Electronic Publication: 2023 Aug 16.

From ownership to custodianship of tumor biopsy tissue in genomic testing: a mixed methods study of patient views.

Autor: Best MC; Institute for Ethics and Society, The University of Notre Dame Australia, Broadway, NSW, Australia., Butow P; Psycho-Oncology Co-operative Research Group, School of Psychology, University of Sydney, Sydney, NSW, Australia., Savard J; Faculty of Health, School of Medicine, Deakin University, Melbourne, VIC, Australia., Newson AJ; Sydney Health Ethics, Faculty of Medicine and Health, Sydney School of Public Health, University of Sydney, Sydney, NSW, Australia., Campbell R; Faculty of Science, School of Psychology, University of Sydney, Sydney, NSW, Australia., Vatter S; Psycho-Oncology Co-operative Research Group, School of Psychology, University of Sydney, Sydney, NSW, Australia., Napier CE; Garvan Institute of Medical Research, Sydney, NSW, Australia., Bartley N; Psycho-Oncology Co-operative Research Group, School of Psychology, University of Sydney, Sydney, NSW, Australia., Tucker K; Hereditary Cancer Centre, Prince of Wales Medical School, Prince of Wales Hospital, University of New South Wales, Randwick, NSW, Australia., Ballinger ML; Garvan Institute of Medical Research, St Vincent's Clinical School, UNSW, Sydney, NSW, Australia., Thomas DM; Garvan Institute of Medical Research, St Vincent's Clinical School, UNSW, Sydney, NSW, Australia.

Publikováno v: The oncologist [Oncologist] 2024 Sep 06; Vol. 29 (9), pp. e1169-e1179.

Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum.

Autor: Fortuno C; Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia., Feng BJ; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Carroll C; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Innella G; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy., Kohlmann W; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Lázaro C; Hereditary Cancer Program, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain.; Hereditary Cancer Program, ONCOBELL, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto Salud Carlos III, Madrid, Spain., Brunet J; Hereditary Cancer Program, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain.; Hereditary Cancer Program, ONCOBELL, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto Salud Carlos III, Madrid, Spain.; Precision Oncology in Girona, IDIBGI, Girona, Spain., Feliubadaló L; Hereditary Cancer Program, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain.; Hereditary Cancer Program, ONCOBELL, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto Salud Carlos III, Madrid, Spain., Iglesias S; Hereditary Cancer Program, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain., Menéndez M; Hereditary Cancer Program, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain., Teulé A; Hereditary Cancer Program, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain.; Hereditary Cancer Program, ONCOBELL, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain., Ballinger ML; St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, New South Wales, Australia.; Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia., Thomas DM; Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.; Centre for Molecular Oncology, Faculty of Medicine, University of New South Wales, New South Wales, Australia., Campbell A; Department of Clinical Genetics, Austin Health, Melbourne, Victoria, Australia., Field M; Familial Cancer Service, Royal North Shore Hospital, St Leonards, New South Wales, Australia., Harris M; Monash Health Familial Cancer Service, Melbourne, Victoria, Australia., Kirk J; Familial Cancer Service, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia., Pachter N; Genetic Services of Western Australia, King Edward Memorial Hospital, Perth, Western Australia, Australia., Poplawski N; Adult Genetics Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.; Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia., Susman R; Genetic Health Queensland, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia., Tucker K; Hereditary Cancer Clinic, Prince of Wales Hospital, Randwick, New South Wales, Australia.; Prince of Wales Clinical School, UNSW Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia., Wallis M; Tasmanian Clinical Genetics Service, Tasmanian Health Service, Royal Hobart Hospital, Hobart, Tasmania, Australia.; School of Medicine and Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia., Williams R; Prince of Wales Clinical School, UNSW Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia.; Prince of Wales Hereditary Cancer Centre, Prince of Wales Hospital, Randwick, New South Wales, Australia., Cops E; Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia., Goldgar D; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., James PA; Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia., Spurdle AB; Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Publikováno v: JCO precision oncology [JCO Precis Oncol] 2024 Feb; Vol. 8, pp. e2300453.

Psychological predictors of cancer patients' and their relatives' attitudes towards the return of genomic sequencing results

Autor: Meiser, B, Butow, P, Davies, G, Napier, CE, Schlub, TE, Bartley, N, Juraskova, I, Ballinger, ML, Thomas, DM, Best, MC, members of the Psychosocial Issues in Genomics in Oncology (PiGeOn) Project, Jacobs, C

This study assessed the psychological predictors of attitudes toward the return of germline genomic sequencing results in cancer patients and their biological relatives with a likely genetic basis for their cancer diagnosis, who completed a questionn

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______363::ebbd78871c1ac82b02473eb664fa6e81
https://hdl.handle.net/10453/163723